EVO SEC Filings: 8-K, 10-Q, S-3 & 424B – Evotec

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 8, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 17, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 14, 2024

NT 20-F

Form NT 20-F - Notification of inability to timely file Form 20-F

Apr 30, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

May 12, 2023

NT 20-F

Form NT 20-F - Notification of inability to timely file Form 20-F

May 2, 2023

News

TYPE

HEADLINE

FILED AT

6-K

Evotec Reports Interim 9M 2026 Results, Reaffirms Full-Year Guidance, and Advances Strategic Collaborations

Nov 5, 2026

6-K

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Oct 15, 2026

6-K

Evotec Announces Preliminary Nine-Months 2026 Results Above Market Expectations

Oct 14, 2026

6-K

Evotec Announces Chief Scientific Officer Transition

Sep 29, 2026

6-K

Just – Evotec Biologics Initiates Phase 1 Clinical Study for Orthopoxvirus Antibodies under U.S. Department of War Program

Sep 9, 2026

6-K

Evotec Reports 6M 2026 Interim Results and Updates Full-Year Outlook

Aug 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

20,000,000 American Depositary Shares-

Nov 5, 2021

425